drugset / Trial / NCT04672356
A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is an open-label, phase I clinical study to evaluate the efficacy, tolerability and safety of recombinant fully human anti-TIGIT antibody (IBI939) in combination with recombinant fully human anti-programmed cell death receptor 1 (PD-1) antibody (sintilimab) in subjects with advanced lung cancer.
Timeline
- Start
- 2021-01-25
- Primary completion
- 2023-01-01
- Completion
- 2023-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI939 | Protein / enzyme biologic | 10 mg/kg | — |
| Subject | IBI939 | Protein / enzyme biologic | 20 mg/kg | — |
| Background | Sintilimab | Monoclonal antibody | — | — |